• Mashup Score: 2

    Before businesses can create an engaging experience with the modern, digital-first consumer, you need to earn their trust. Learn how with our three tips.

    Tweet Tweets with this article
    • Establish values. Ensure data privacy. Enable a customized experience. @mitel has some tips on how #UC #tech can help your business practice the 3️⃣ E's of #CX and gain trust with consumers 👇. https://t.co/D7jY5Jrttr https://t.co/RUvlG6KrDG

  • Mashup Score: 2

    Ulcerative colitis often leads to digestion issues and a change in diet and may cause nutritional deficiencies. Supplements may help boost nutrient levels and prevent worsening of symptoms.

    Tweet Tweets with this article
    • A commonly asked question from patients with #IBD and #ulcerativecolitis around the role of supplements, probiotics in the management of #IBD @medicalnewstoday took the opportunity to provide more awareness and education around #supplements in #UC https://t.co/iyQ83zRQBy https://t.co/NEEZkrcak2

  • Mashup Score: 1
    Wolters Kluwer Health - 10 month(s) ago

    JavaScript Error JavaScript has been disabled on your browser. You must enable it to continue. Here’s how to enable JavaScript in the following browsers: Internet Explorer From the Tools menu, select Options Click the Content tab Select Enable JavaScript Firefox From the Tools…

    Tweet Tweets with this article
    • The Nancy Histopathology Index has a modest positive correlation with clinical, laboratory, and endoscopic indices of disease activity in pediatric patients with #UC. https://t.co/RcJILk4Z6I https://t.co/7PZ66Kqtf7

  • Mashup Score: 0

    Vedolizumab more effectively induced remission compared with placebo in patients with chronic pouchitis following ileal pouch-anal anastomosis for ulcerative colitis, according to research in The New England Journal of Medicine.“Idiopathic inflammation of the pouch — referred to as pouchitis — is the most common long-term complication of ileal pouch-anal anastomosis (IPAA); it

    Tweet Tweets with this article
    • #ICYMI from @NEJM: #Vedolizumab induces remission in more than 30% of #UC patients with chronic #pouchitis #GITwitter #MedTwitter #IBD https://t.co/oFUIcvla3k